Shares of Vir Biotechnology, Inc. (VIR) surged 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its chronic hepatitis delta (CHD) treatment. The biotechnology company revealed promising data from its SOLSTICE trial, evaluating the combination of tobevibart and elebsiran.

According to results presented at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD) and published in the New England Journal of Medicine, 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus (HDV) RNA at Week 48. The treatment was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported.

Investors responded positively to this news, as it represents a significant step forward in addressing an unmet medical need. The combination therapy has already received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency. Vir Biotechnology is now conducting the ECLIPSE registrational program for the combination therapy, with topline data expected in the first quarter of 2027. This progress in the company's pipeline appears to be driving the stock's impressive performance.